Presentation is loading. Please wait.

Presentation is loading. Please wait.

ASX: NRT NASDAQ: NVGN biotechandmoney London 3-4 February 2015 Graham Kelly CEO & Executive Chairman.

Similar presentations


Presentation on theme: "ASX: NRT NASDAQ: NVGN biotechandmoney London 3-4 February 2015 Graham Kelly CEO & Executive Chairman."— Presentation transcript:

1 ASX: NRT NASDAQ: NVGN biotechandmoney London 3-4 February 2015 Graham Kelly CEO & Executive Chairman

2 The future of cancer therapy Company profile 2 Fields:  oncology  neurodegenerative/musculodegenerative diseases  orphan childhood genetic disorders  regenerative medicine  autoimmune diseases Public Listed: ASX (NRT) and Nasdaq (NVGN) Two proprietary technologies: 2 new drug targets Drug discovery company

3 The future of cancer therapy Two first-in-class drug technologies 3 Super-Benzopyrans Anti-Tropomyosins Small molecules New chemical entities (multiple patent families) Pleiotropic (multiple targets; electron transfer enzymes; ? gene transcription factors) Pluripotent tissue stem cells primary target Small molecules New chemical entities (multiple patent families) Specific target Tropomyosin isoform Tm5NM1 Small molecules New chemical entities (multiple patent families) Specific target Tropomyosin isoform Tm5NM1

4 The future of cancer therapy What do I get as a shareholder? 4 Super-Benzopyrans Anti-Tropomyosins Potent ability to kill the full hierarchy of cells within a tumor  cancer stem cells  progenitor cancer cells  daughter cancer cells  to prevent cancer recurrence  potential to become standard of care for both first-line therapy and salvage therapy across most forms of cancer First-in-class drugs targeting the cancer cell’s micro-filaments  complement the action of the most widely used drugs (taxanes/vinca alkaloids) in oncology  potential to become first-line standard of care with taxanes/vinca alkaloids for a wide range of cancers First-in-class drugs targeting the cancer cell’s micro-filaments  complement the action of the most widely used drugs (taxanes/vinca alkaloids) in oncology  potential to become first-line standard of care with taxanes/vinca alkaloids for a wide range of cancers

5 The future of cancer therapy PreclinicalPhase 1 Cantrixil™  Malignant ascites  Malignant pleural effusion  Ovarian cancer TRXE-009  Primary adult brain cancers  Secondary adult brain cancers  Primary pediatric brain cancers  Malignant melanoma TRXE-0025  Prostate cancer Anisina™  Melanoma  Prostate cancer  Neuroblastoma 5 Pipeline

6 The future of cancer therapy 6 Potential value-drivers Cantrixil  First purpose-built intra-cavity chemotherapy  Opportunity to become standard of care for malignant ascites and malignant pleural effusion, terminal conditions affecting approximately 30% of all cancer patients TRXE-009  First chemotherapy to preferentially target tumors of cells with embryonic neural tube/neural crest origins  Opportunity to become first drug to treat both primary and secondary brain cancers, secondary melanoma in particular TRXE-0025  Opportunity to be first cytotoxic chemotherapy to kill the full hierarchy of cells within prostate cancer and, in so doing, deliver meaningful survival benefits to patients with castrate-resistant disease Anisina  Opportunity to become first-line, stand-of-care for wide range of cancers in combination with taxanes and vinca alkaloids

7 ASX: NRT NASDAQ: NVGN biotechandmoney London 3-4 February 2015 Contact: Dr Graham Kelly


Download ppt "ASX: NRT NASDAQ: NVGN biotechandmoney London 3-4 February 2015 Graham Kelly CEO & Executive Chairman."

Similar presentations


Ads by Google